德視佳(01846.HK)附屬共斥1.19億元收購瑞士及英國眼科業務
德視佳(01846.HK)表示,附屬EuroEyes Swiss購入主要於瑞士從事眼科服務業務的Betterview Swiss的瑞士資產,總代價爲1,201萬瑞士法郎,相當於約1.17億港元。
同時,其附屬EuroEyes UK購入主要於英國從事眼科服務業務的Betterview UK的英國資產,總代價爲20萬瑞士法郎,相當於約194.89萬港元。
集團認爲,收購事項將使其能夠立即在瑞士主要城市建立業務據點,並鞏固其在倫敦(歐洲屈光手術主要市場之一)的地位。組成資產的診所已產生經常性收入並擁有穩固的客戶羣。收購事項亦代表集團向重要歐洲市場瑞士進行策略性擴張並鞏固其在英國的市場地位,進而拓展集團的業務地域分佈,並預期將對集團長期增長作出積極貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.